Adam Januszewski, St Bartholomew's Hospital in London, provides an overview of a session he chaired at the BTOG 2024 congress focusing on therapeutics, particularly exploring newer classes of drugs like antibody drug conjugates (ASCs) and bispecific T cell engagers (BiTEs). With Prof. Egbert Smit and Prof. Fiona Blackwell as speakers, discussions delved into the potential use of these agents in patients with lung cancer. The session covered trials using teratoma in small cell lung cancer (SCLC), emphasizing promising response rates and the need for further investigation amid challenges regarding side effects. Additionally, Prof. Egbert Schmidt highlighted the role of ADCs, particularly addressing patient selection criteria and the efficacy of targeting mutations like HER2. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
